{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T13:56:57Z","timestamp":1762869417634},"reference-count":28,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,8,6]]},"DOI":"10.7759\/cureus.66338","type":"journal-article","created":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T05:25:41Z","timestamp":1723008341000},"source":"Crossref","is-referenced-by-count":1,"title":["Epstein-Barr Virus-Associated Aggressive Natural Killer Cell Leukemia: Challenges and Emerging Therapies"],"prefix":"10.7759","author":[{"given":"Ahmad","family":"Hamdan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chun","family":"Chou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Rust","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Strand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.2147\/IDR.S375624","article-title":"Treatment options for Epstein-Barr virus-related disorders of the central nervous system","volume":"16","author":"Andersen O","year":"2023","unstructured":"Andersen O, Ernberg I, Hedstr\u00f6m AK. Treatment options for Epstein-Barr virus-related disorders of the central nervous system. Infect Drug Resist. 2023, 16:4599-620. 10.2147\/IDR.S375624","journal-title":"Infect Drug Resist"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232214389","article-title":"Epstein-Barr virus (EBV) epithelial associated malignancies: exploring pathologies and current treatments","volume":"23","author":"Shechter O","year":"2022","unstructured":"Shechter O, Sausen DG, Gallo ES, Dahari H, Borenstein R. Epstein-Barr virus (EBV) epithelial associated malignancies: exploring pathologies and current treatments. Int J Mol Sci. 2022, 23:10.3390\/ijms232214389","journal-title":"Int J Mol Sci"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13205189","article-title":"Epstein-Barr virus-associated malignancies and immune escape: the role of the tumor microenvironment and tumor cell evasion strategies","volume":"13","author":"Bauer M","year":"2021","unstructured":"Bauer M, Jasinski-Bergner S, Mandelboim O, Wickenhauser C, Seliger B. Epstein-Barr virus-associated malignancies and immune escape: the role of the tumor microenvironment and tumor cell evasion strategies. Cancers (Basel). 2021, 13:10.3390\/cancers13205189","journal-title":"Cancers (Basel)"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-021-03824-y","article-title":"Estimating the global burden of Epstein-Barr virus-related cancers","volume":"148","author":"Wong Y","year":"2022","unstructured":"Wong Y, Meehan MT, Burrows SR, Doolan DL, Miles JJ. Estimating the global burden of Epstein-Barr virus-related cancers. J Cancer Res Clin Oncol. 2022, 148:31-46. 10.1007\/s00432-021-03824-y","journal-title":"J Cancer Res Clin Oncol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2019.00071","article-title":"Epstein-Barr virus-associated T and NK-cell lymphoproliferative diseases","volume":"7","author":"Kim WY","year":"2019","unstructured":"Kim WY, Montes-Mojarro IA, Fend F, Quintanilla-Martinez L. Epstein-Barr virus-associated T and NK-cell lymphoproliferative diseases. Front Pediatr. 2019, 7:10.3389\/fped.2019.00071","journal-title":"Front Pediatr"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-017-0021-z","article-title":"Aggressive NK-cell leukemia: clinical subtypes, molecular features, and treatment outcomes","volume":"7","author":"Tang YT","year":"2017","unstructured":"Tang YT, Wang D, Luo H, et al.. Aggressive NK-cell leukemia: clinical subtypes, molecular features, and treatment outcomes. Blood Cancer J. 2017, 7:660. 10.1038\/s41408-017-0021-z","journal-title":"Blood Cancer J"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.22537","article-title":"Aggressive natural killer cell leukemia: a brief overview of its genomic landscape, histological features, and current management","volume":"14","author":"Sumbly V","year":"2022","unstructured":"Sumbly V, Vest M, Landry I. Aggressive natural killer cell leukemia: a brief overview of its genomic landscape, histological features, and current management. Cureus. 2022, 14:10.7759\/cureus.22537","journal-title":"Cureus"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.20517\/2394-4722.2021.157","article-title":"Progress in the treatment of NK-cell lymphoma\/leukemia","volume":"7","author":"Fujimoto A","year":"2021","unstructured":"Fujimoto A, Suzuki R. Progress in the treatment of NK-cell lymphoma\/leukemia. J Cancer Metastasis Treat. 2021, 7:10.20517\/2394-4722.2021.157","journal-title":"J Cancer Metastasis Treat"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-03-785931","article-title":"How I treat T-cell chronic active Epstein-Barr virus disease","volume":"131","author":"Bollard CM","year":"2018","unstructured":"Bollard CM, Cohen JI. How I treat T-cell chronic active Epstein-Barr virus disease. Blood. 2018, 131:2899-905. 10.1182\/blood-2018-03-785931","journal-title":"Blood"},{"key":"ref10","article-title":"Etiology of Burkitt's lymphoma - an alternative hypothesis to a vectored virus","volume":"42","author":"Burkitt DP","year":"1969","unstructured":"Burkitt DP. Etiology of Burkitt's lymphoma - an alternative hypothesis to a vectored virus. J Natl Cancer Inst. 1969, 42:19-28.","journal-title":"J Natl Cancer Inst"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1059133","article-title":"EBV-associated diseases: current therapeutics and emerging technologies","volume":"13","author":"Chakravorty S","year":"2022","unstructured":"Chakravorty S, Afzali B, Kazemian M. EBV-associated diseases: current therapeutics and emerging technologies. Front Immunol. 2022, 13:10.3389\/fimmu.2022.1059133","journal-title":"Front Immunol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00713","article-title":"The global landscape of EBV-associated tumors","volume":"9","author":"Shannon-Lowe C","year":"2019","unstructured":"Shannon-Lowe C, Rickinson A. The global landscape of EBV-associated tumors. Front Oncol. 2019, 9:10.3389\/fonc.2019.00713","journal-title":"Front Oncol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1186\/1750-9378-9-38","article-title":"Global burden of deaths from Epstein-Barr virus attributable malignancies 1990-2010","volume":"9","author":"Khan G","year":"2014","unstructured":"Khan G, Hashim MJ. Global burden of deaths from Epstein-Barr virus attributable malignancies 1990-2010. Infect Agent Cancer. 2014, 9:10.1186\/1750-9378-9-38","journal-title":"Infect Agent Cancer"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2019.00014","article-title":"Advances in the study of chronic active Epstein-Barr virus infection: clinical features under the 2016 WHO classification and mechanisms of development","volume":"7","author":"Arai A","year":"2019","unstructured":"Arai A. Advances in the study of chronic active Epstein-Barr virus infection: clinical features under the 2016 WHO classification and mechanisms of development. Front Pediatr. 2019, 7:10.3389\/fped.2019.00014","journal-title":"Front Pediatr"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1086\/423285","article-title":"Quantitative analysis of Epstein-Barr virus (EBV)-specific CD8+ T cells in patients with chronic active EBV infection","volume":"190","author":"Sugaya N","year":"2004","unstructured":"Sugaya N, Kimura H, Hara S, et al.. Quantitative analysis of Epstein-Barr virus (EBV)-specific CD8+ T cells in patients with chronic active EBV infection. J Infect Dis. 2004, 190:985-8. 10.1086\/423285","journal-title":"J Infect Dis"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0182682","article-title":"Correction: EBV induces persistent NF-\u03baB activation and contributes to survival of EBV-positive neoplastic T- or NK-cells","volume":"12","author":"Takada H","year":"2017","unstructured":"Takada H, Imadome KI, Shibayama H, et al.. Correction: EBV induces persistent NF-\u03baB activation and contributes to survival of EBV-positive neoplastic T- or NK-cells. PLoS One. 2017, 12:10.1371\/journal.pone.0182682","journal-title":"PLoS One"},{"key":"ref17","article-title":"Chronic active Epstein-Barr virus infection progresses to aggressive NK cell leukemia with a poor prognosis","volume":"13","author":"Hu X","year":"2021","unstructured":"Hu X, Yang Y, Chen L, Wan Y, Sheng L, Bao Y, Zheng M. Chronic active Epstein-Barr virus infection progresses to aggressive NK cell leukemia with a poor prognosis. Am J Transl Res. 2021, 13:12006-15.","journal-title":"Am J Transl Res"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2008.23.2.185","article-title":"The spectrum of Epstein-Barr virus-associated lymphoproliferative disease in Korea: incidence of disease entities by age groups","volume":"23","author":"Cho EY","year":"2008","unstructured":"Cho EY, Kim KH, Kim WS, Yoo KH, Koo HH, Ko YH. The spectrum of Epstein-Barr virus-associated lymphoproliferative disease in Korea: incidence of disease entities by age groups. J Korean Med Sci. 2008, 23:185-92. 10.3346\/jkms.2008.23.2.185","journal-title":"J Korean Med Sci"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-10-381921","article-title":"EBV-associated T\/NK-cell lymphoproliferative diseases in nonimmunocompromised hosts: prospective analysis of 108 cases","volume":"119","author":"Kimura H","year":"2012","unstructured":"Kimura H, Ito Y, Kawabe S, et al.. EBV-associated T\/NK-cell lymphoproliferative diseases in nonimmunocompromised hosts: prospective analysis of 108 cases. Blood. 2012, 119:673-86. 10.1182\/blood-2011-10-381921","journal-title":"Blood"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020001451","article-title":"Nationwide survey of systemic chronic active EBV infection in Japan in accordance with the new WHO classification","volume":"4","author":"Yonese I","year":"2020","unstructured":"Yonese I, Sakashita C, Imadome KI, et al.. Nationwide survey of systemic chronic active EBV infection in Japan in accordance with the new WHO classification. Blood Adv. 2020, 4:2918-26. 10.1182\/bloodadvances.2020001451","journal-title":"Blood Adv"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.25780","article-title":"STAT3 is constitutively activated in chronic active Epstein-Barr virus infection and can be a therapeutic target","volume":"9","author":"Onozawa E","year":"2018","unstructured":"Onozawa E, Shibayama H, Takada H, et al.. STAT3 is constitutively activated in chronic active Epstein-Barr virus infection and can be a therapeutic target. Oncotarget. 2018, 9:31077-89. 10.18632\/oncotarget.25780","journal-title":"Oncotarget"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.710400","article-title":"Ruxolitinib in patients with chronic active Epstein-Barr virus infection: a retrospective, single-center study","volume":"12","author":"Song Y","year":"2021","unstructured":"Song Y, Wang J, Wang Y, Wang Z. Ruxolitinib in patients with chronic active Epstein-Barr virus infection: a retrospective, single-center study. Front Pharmacol. 2021, 12:10.3389\/fphar.2021.710400","journal-title":"Front Pharmacol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1177\/20587384211002621","article-title":"A review: mechanism of action of antiviral drugs","volume":"35","author":"Kausar S","year":"2021","unstructured":"Kausar S, Said Khan F, Ishaq Mujeeb Ur Rehman M, et al.. A review: mechanism of action of antiviral drugs. Int J Immunopathol Pharmacol. 2021, 35:10.1177\/20587384211002621","journal-title":"Int J Immunopathol Pharmacol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.11.2923","article-title":"The Epstein-Barr virus thymidine kinase does not phosphorylate ganciclovir or acyclovir and demonstrates a narrow substrate specificity compared to the herpes simplex virus type 1 thymidine kinase","volume":"42","author":"Gustafson EA","year":"1998","unstructured":"Gustafson EA, Chillemi AC, Sage DR, Fingeroth JD. The Epstein-Barr virus thymidine kinase does not phosphorylate ganciclovir or acyclovir and demonstrates a narrow substrate specificity compared to the herpes simplex virus type 1 thymidine kinase. Antimicrob Agents Chemother. 1998, 42:2923-31. 10.1128\/AAC.42.11.2923","journal-title":"Antimicrob Agents Chemother"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02487-09","article-title":"The Epstein-Barr virus (EBV)-encoded protein kinase, EBV-PK, but not the thymidine kinase (EBV-TK), is required for ganciclovir and acyclovir inhibition of lytic viral production","volume":"84","author":"Meng Q","year":"2010","unstructured":"Meng Q, Hagemeier SR, Fingeroth JD, Gershburg E, Pagano JS, Kenney SC. The Epstein-Barr virus (EBV)-encoded protein kinase, EBV-PK, but not the thymidine kinase (EBV-TK), is required for ganciclovir and acyclovir inhibition of lytic viral production. J Virol. 2010, 84:4534-42. 10.1128\/JVI.02487-09","journal-title":"J Virol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.29698","article-title":"Inhibition of class I histone deacetylases by romidepsin potently induces Epstein-Barr virus lytic cycle and mediates enhanced cell death with ganciclovir","volume":"138","author":"Hui KF","year":"2016","unstructured":"Hui KF, Cheung AK, Choi CK, et al.. Inhibition of class I histone deacetylases by romidepsin potently induces Epstein-Barr virus lytic cycle and mediates enhanced cell death with ganciclovir. Int J Cancer. 2016, 138:125-36. 10.1002\/ijc.29698","journal-title":"Int J Cancer"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1093\/mutage\/15.2.177","article-title":"Cytogenetic genotoxicity of anti-herpes purine nucleoside analogues in CHO cells expressing the thymidine kinase gene of herpes simplex virus type 1: comparison of ganciclovir, penciclovir and aciclovir","volume":"15","author":"Thust R","year":"2000","unstructured":"Thust R, Tomicic M, Kl\u00f6cking R, Wutzler P, Kaina B. Cytogenetic genotoxicity of anti-herpes purine nucleoside analogues in CHO cells expressing the thymidine kinase gene of herpes simplex virus type 1: comparison of ganciclovir, penciclovir and aciclovir. Mutagenesis. 2000, 15:177-84. 10.1093\/mutage\/15.2.177","journal-title":"Mutagenesis"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12102900","article-title":"Aggressive NK cell leukemia: current state of the art","volume":"12","author":"El Hussein S","year":"2020","unstructured":"El Hussein S, Medeiros LJ, Khoury JD. Aggressive NK cell leukemia: current state of the art. Cancers (Basel). 2020, 12:10.3390\/cancers12102900","journal-title":"Cancers (Basel)"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/270131-epstein-barr-virus-associated-aggressive-natural-killer-cell-leukemia-challenges-and-emerging-therapies","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T05:25:45Z","timestamp":1723008345000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/270131-epstein-barr-virus-associated-aggressive-natural-killer-cell-leukemia-challenges-and-emerging-therapies"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,6]]},"references-count":28,"URL":"https:\/\/doi.org\/10.7759\/cureus.66338","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8,6]]}}}